KNDO | May 19, 2023
The University of Washington School of Medicine is conducting a study on the therapeutic value of psychedelic mushrooms led by Nathan Sackett, MD.
News & Stories
WA authorizes UW study of ‘magic mushrooms’ as PTSD treatment
MyNorthwest | May 17, 2023
Governor Jay Inslee signed Senate Bill 5263 into law, which mandated a study into psilocybin as well as the creation of a regulatory body for the possible recreational and medical use of the drug. Leading the upcoming study will be Dr. Nathan Sackett, with the University of Washington’s Department of Psychiatry and Behavioral Sciences.
This is your body on alcohol
Right as Rain | May 17, 2023
Alcohol is so normalized in our culture that we often forget its effects on our bodies, including long-term consequences of alcohol use like cardiovascular disease, anxiety and more. Nathan Sackett is quoted.
Psychiatrist to lead state-mandated psilocybin trial
UW Medicine Newsroom | May 16, 2023
UW Medicine, led by the Center for Novel Therapeutics in Addiction Psychiatry, will facilitate a small-scale study to explore the potential benefit of psychedelic mushrooms with psychotherapy.
Center for Novel Therapeutics in Addiction Psychiatry is official
Department of Psychiatry and Behavioral Sciences | March 30, 2023
The UW’s Office of Research facilitates the development of new research initiatives that cut across traditional disciplinary boundaries and sanctions the creation of new interdisciplinary Centers, Institutes, and Programs collectively referred to as ‘Organized Research Units’ (ORUs). The Center for Novel Therapeutics in Addiction Psychiatry (NTAP) is the latest initiative to become an official UW Research Center.
Can you get life insurance if you take psychedelics?
Policygenius | December 30, 2022
Over the last six years, psychedelic drugs have gained increasing acceptance in the medical and legal realms as legitimate treatments for mental health conditions. Nathan Sackett, MD, MS, says researchers are finding growing evidence that psychedelics can help treat conditions like depression, anxiety, and substance abuse.
New hope for treatment-resistant depression with ketamine
Right as Rain | July 5, 2022
Ketamine can help alleviate symptoms of depression and lessen suicidal thoughts quickly, but ketamine treatment is not for everyone, says Nathan Sackett, MD, MS.
Inside the Seattle lecture room where experts are brainstorming the future of psychedelic research
The Seattle Times | April 23, 2022
Scientists, doctors, advocacy workers, and other community members gathered to discuss the next frontier of treating substance-use disorders and addiction: psychedelics. The meeting was convened by the Center for Novel Therapeutics in Addiction Psychiatry led by Nathan Sackett, MD.
Seattle’s psychedelic revolution has arrived
Seattle Met | February 22, 2022
Seattle became the largest U.S. city to decriminalize psychedelic drugs. To be clear, decriminalization isn’t legalization, and the gateway legislation doesn’t apply to LSD, MDMA or ketamine. But it may signal a more permissive psychedelic future. Nathan Sackett, MD, RS, RN, is quoted.
Washington lawmakers considering a bill to legalize psilocybin for medical treatment
KXLY.com | February 2, 2022
Washington lawmakers will consider legalizing the use of psilocybin to treat various illnesses like PTSD and depression. Nathan Sackett, MD, MS, told the committee: "Evidence currently suggests that psilocybin, when given in a controlled environment under the care of a provider, may significantly reduce symptoms of depression, anxiety, trauma and a range of substance abuse disorders."